Amgen 386 for Recurrent Glioblastoma

• Sponsor: Dana-Farber Cancer Institute (Other)
• Overall Status: Completed
• CT.gov ID: NCT01290263
• Collaborator: Amgen (Industry)
• Enrollment: 48
• Locations: 6
• Arms: 2
• Duration (Months): 73
• Patients Per Site: 8
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

Primary Objectives

Cohort A -- monotherapy:

To determine the efficacy of AMG 386 in participants with recurrent glioblastoma (GBM) as measured by 6-month progression-free survival (PFS6)

Cohort B - combination therapy:

Phase I To determine the maximum tolerated dose of AMG 386 in combination with bevacizumab given at 10mg/kg every 2 weeks in participants with recurrent glioblastoma.

Phase II To determine the efficacy of AMG 386 plus bevacizumab in participants with recurrent glioblastoma (GBM) as measured by 6-month progression-free survival (PFS6).

Secondary Objectives:

To evaluate radiographic response in both cohort populations. To evaluate overall survival in both cohort populations. To assess time-to-progression in both cohort populations. To investigate the safety profile in both cohort populations.

Exploratory Objectives:

To evaluate expression of factors associated with tumor angiogenesis using a multiples cytokine assay among participants undergoing therapy with AMG 386 with response to therapy and development of resistance.

This is an open-label Phase I/II study of AMG 386 monotherapy and AMG 386 in combination with bevacizumab. Two cohorts will accrue and will be assessed sequentially. Each cohort will enroll participants with recurrent GBM. Cohort A will assess recurrent GBM participants who receive AMG 386 monotherapy at 30 g/kg every week. (Cohort A initially accrued at a dose of 15mg/kg, but this was increased to 30 mg/kg every week following an amendment). Cohort B will assess recurrent GBM participants who receive weekly AMG 386 plus bi-weekly bevacizumab (10mg/kg). Cohort B will start with a Phase I component to determine the MTD of AMG 386 that is safe when used in combination with bevacizumab. AMG 386 is administered intravenously, and, when used in combination with intravenous bevacizumab, will be administered first.

Patients will be required to come to the clinic weekly for study drug administration.

For study purposes, a cycle of therapy will be 4 weeks. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance with study follow-up, or withdrawal of consent.

The estimated rate of accrual is 60 participants per year. The estimated date of accrual completion is 1.5 years from study initiation. The estimated date of study completion will be approximately 12 months from enrollment of the last study participant.

Condition or Disease	Intervention/Treatment	Phase
Glioblastoma Multiforme	Drug: Amgen 386; Drug: Bevacizumab	Phase 1/Phase 2

Study Design

• Study Type: Interventional
• Actual Enrollment: 48 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase I/II Study of Amgen 386 With and Without Bevacizumab for Recurrent Glioblastoma
• Study Start Date: Dec 1, 2010
• Actual Primary Completion Date: Jul 1, 2015
• Actual Study Completion Date: Jan 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Amgen 386 Cohort A will assess recurrent Glioblastoma Multiforme (GBM) patients who receive AMG 386 monotherapy at 30mg/kg every week. As of August 1, 2013, Cohort A was closed to new accrual following early interim analysis of first 10 participants enrolled on study. None of these patients had achieved stable disease or response at their initial evaluation after 1-2 months of study therapy. Therefore, study investigators and sponsor agreed that the level of single-agent anti-tumor activity associated with AMG386 for recurrent glioblastoma patients is most likely insufficient to satisfy the stopping rule for low efficacy outlined in Section 14.5 for Cohort A.	Drug: Amgen 386; For Cohort A, AMG 386 will be administered intravenously at 30 mg/kg every week. For Cohort B Phase I, AMG 386 will be administered intravenously at beginning at starting dose level of 15 mg/kg every week. For Cohort B Phase II, AMG 386 will be administered intravenously at the maximum tolerated dose determined in the Phase I portion of the study every week.; Other Names: Trebananib
Experimental: Amgen 386 and Bevacizumab Cohort B will assess recurrent Glioblastoma Multiforme(GBM) patients who receive AMG 386 plus bevacizumab. Because the maximum tolerated dose of this combination therapy has not yet been established, a 3x3 Phase I study was used to determine the maximum tolerated dose. As of June 6, 2014, the MTD was determined to be AMG386 30 mg/kg administered intravenously every week(dose level +1) in combination with bevacizumab at 10mg/kg administered intravenously every other week. As of July 25, 2014 the Cohort B, Phase II portion of the study was opened to accrual.	Drug: Amgen 386; For Cohort A, AMG 386 will be administered intravenously at 30 mg/kg every week. For Cohort B Phase I, AMG 386 will be administered intravenously at beginning at starting dose level of 15 mg/kg every week. For Cohort B Phase II, AMG 386 will be administered intravenously at the maximum tolerated dose determined in the Phase I portion of the study every week.; Other Names: Trebananib ; Drug: Bevacizumab; The dose of bevacizumab will be 10 mg/kg and will be administered intravenously every other week.; Other Names: Avastin

Outcome Measures

Primary Outcome Measures

1. 6-Month Progression-Free Survival (PFS6) [Cohort A and Cohort B] [6 months]

   PFS6 is the proportion of patients remaining alive and progression-free at 6-months from study entry. Progressive disease was established based on Response Assessment in Neuro-Oncology (RANO) criteria (Wen et al JCO 2010). RANO criteria has 5 potential categories: Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive disease (PD) and Unknown status. CR: disappearance of all enhancing lesions, stable or improved non-enhancing lesions, and stable or improved clinically. PR: >= 50% decrease in sum of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, stable or improved non- enhancing lesions, and stable or improved clinically. PD: > 25% increase in sum of perpendicular diameters of all measurable enhancing lesions, significant increase of non-enhancing lesions, any new lesions, clear clinical deterioration, failure to return for evaluation due to death or deteriorating condition. SD: d

2. AMG 386 Maximum Tolerated Dose (MTD) [Cohort B Phase I] [Participants were assessed weekly while on study; the observation period for MTD evaluation was the first 28 days of study treatment.]

   The MTD of weekly AMG 386 intravenously (IV) in combination with bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle is determined by the number of participants who experience a dose limiting toxicity (DLT). See subsequent primary outcome measure for the DLT definition. The MTD is defined as the highest dose at which fewer than one-third of patients experience a DLT. If no DLTs are observed, the MTD is not reached but the highest dose received may be the Recommended Phase II Dose (RP2D).

3. AMG 386 Dose Limiting Toxicity (DLT) [Cohort B Phase I] [Participants were assessed weekly while on study; the observation period for DLT evaluation was the first 28 days of study treatment.]

   A DLT is defined as an adverse event that (a) is related to the AMG 386 and/or bevacizumab with an attribution of possible, probable, or definite, and (b) occurs during and/or begins during the first 28 days of the study treatment, and (c) meets any of the following criteria: >= grade 3 thrombocytopenia; grade 4 neutropenia lasting > 7 days; grade 4 anemia lasting > 7 days despite transfusion or growth factors; febrile neutropenia if ANC<0.5x10^9/L; clinically significant grade 3 non-hematologic toxicity despite maximal medical therapy lasting > 7 days, with the exception of grade 3 proteinuria which was considered a DLT if lasting > 14 days; grade 3 non-hematologic toxicity resulting in study drug discontinuation; grade 4 non-hematologic toxicity; >= grade 1 new CNS hemorrhage; >= grade 2 non-CNS hemorrhage.

Secondary Outcome Measures

1. Best Radiographic Response [Cohort A and Cohort B] [Disease was assessed radiographically for response every 8 weeks.]

   Radiographic response was established based on Response Assessment in Neuro-Oncology (RANO) criteria (Wen et al JCO 2010) with 5 potential categories: Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive disease (PD) and Unknown status. CR: disappearance of all enhancing lesions, stable or improved non-enhancing lesions, and stable or improved clinically. PR: >= 50% decrease in sum of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, stable or improved non- enhancing lesions, and stable or improved clinically. PD: > 25% increase in sum of perpendicular diameters of all measurable enhancing lesions, significant increase of non-enhancing lesions, any new lesions, clear clinical deterioration, failure to return for evaluation due to death or deteriorating condition. SD: does not qualify for CR, PR or PD, stable non-enhancing lesions, and stable clinically.

2. Overall Survival (OS) [Cohort A and Cohort B] [Participants were followed long-term for survival every 3 to 4 months from the end of treatment until death or lost to follow-up. On Cohort A and B participants were followed up to 554 days and 442 days.]

   OS based on Kaplan-Meier is defined as the time from study entry to death or date last known alive.

3. Progression-Free Survival (PFS) [Cohort A and Cohort B] [Disease was assessed radiographically to document clinical progression every cycle on treatment and post-treatment every 8 weeks. On Cohort A and B participants were followed for progression up to 36 days and 166 days.]

   PFS based on Kaplan-Meier is defined as the time from study entry to the earliest documentation of disease progression or death. Progressive disease was established based on Response Assessment in Neuro-Oncology (RANO) criteria (Wen et al JCO 2010).

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria

• Signed informed consent approved by the Institutional Review Board prior to participant entry

• Age ≥ 18 years.

• Karnofsky ≥ 70%

• Participant must be able and willing to comply with study and/or follow-up procedures Participants must have histologically confirmed diagnosis of GBM patients with either grade III or IV malignant glioma are eligible to the Phase I portion of the study) and radiographic evidence of recurrence or disease progression (defined as either a greater than 25% increase in the largest bidimensional product of enhancement, a new enhancing lesion, or significant increase in T2 FLAIR) following prior therapy (i.e. chemotherapy, XRT, other investigational therapies).

• No more than 2 prior episodes of progressive disease (patients with more than 2 prior episodes of progressive disease are eligible for the Cohort B, Phase I portion of this study)

• An interval of at least 4 weeks (to start of study agent) between prior surgical resection or one week from stereotactic biopsy

• An interval of at least 12 weeks (to start of study agent) from the end of prior radiotherapy unless there is a new area of enhancement consistent with recurrent tumor outside of the radiation field, or there is histological confirmation of unequivocal tumor progression

• From the projected start of scheduled study treatment, the following time periods must have relapsed: 4 weeks (or 5 half lives, whichever is shorter) from any investigational agent, 4 weeks (or 5 half lives, whichever is shorter) from cytotoxic therapy (except 23 days for temozolomide and 6 weeks from nitrosoureas), 6 weeks from antibodies (or 5 half lives, whichever is shorter), or 4 weeks (or 5 half lives, whichever is shorter) from other anti-tumor therapies.

• Participants must have recovered to a grade 0 or 1 from the toxic effects of prior therapy (with the exception of lymphopenia, which is common after therapy with temozolomide, and alopecia).

• No evidence of hemorrhage on the baseline MRI or CT scan other than those that are ≤ grade 1 and either post-operative or stable on at least two consecutive scans. Clinical Labs - performed within 14 days prior to enrollment

• Hematocrit ≥ 29%, ANC ≥ 1,000 cells/μl, platelets ≥ 100,000 cells/μl ;

• Serum creatinine ≤ 1.5 mg/dl, serum SGOT and bilirubin ≤ 1.5 times upper limit of normal;

• PTT or aPTT ≤ 1.5 times upper limit of normal and INR ≤ 1.5

• Calculated creatinine clearance ≥ 40 mL/min according to the Cockcroft-Gault formula OR per 24 hour urine collection

• Urinary protein quantitative value of < 30 mg/dL in urinalysis or <1+ on dipstick, unless quantitative protein is < 1000 mg in a 24 hour urine sample;

• Participants of child-bearing potential who have not undergone a bilateral salpingo-oophorectomy and are sexually active must consent to use an accepted and highly effective non-hormonal method of contraception (i.e. double barrier method [e.g., condom plus diaphragm]) from signing the informed consent through 6 months after last dose of study drug.

Exclusion Criteria:

• Prior anti-angiogenic therapy targeting VEGF or VEGF receptor including prior bevacizumab.

• Prior AMG 386 therapy or other molecules that inhibit the angiopoietins or Tie2 receptor.

• Co-medication that may interfere with study results; e.g. immunosuppressive agents other than corticosteroids.

• Active infection requiring intravenous antibiotics

• Current or within 30 days prior to enrollment treatment with immune modulators such as systemic cyclosporine and tacrolimus.

• Current us of warfarin sodium or any other Coumadin-derivative anticoagulant. Participant must be off Coumadin-derivative anticoagulants for at least seven days prior to starting study drug. ow molecular weight heparin is allowed.

• Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than supportive care or epidemiologic studies.

• Herbal preparations/medications are not allowed throughout the study. These herbal medications include, but are not limited to: St. John's wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, ginseng. Participants should stop using any herbal medications 7 days prior to first dose of study drug.

• History of clinically significant bleeding within 6 months of enrollment

• History of allergic reactions to bacterially produced proteins

• Known hypersensitivity to any component of bevacizumab (cohort B only)

• Known sensitivity to any of the products to be administered during dosing

• History of venous or arterial thromboembolism within 12 months prior to enrollment.

• Severe hepatic insufficiency (ongoing grade 3 or greater hepatic adverse events) or known active chronic hepatitis.

• Inadequately controlled hypertension (defined as systolic blood pressure >140 and/or diastolic blood pressure > 90 mmHg). The use of anti-hypertensive medications to control hypertension is permitted.

• Any prior history of hypertensive crisis or hypertensive encephalopathy

• Clinically significant cardiovascular disease within 12 months prior to enrollment, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication, percutaneous transluminal coronary angioplasty/stent.

• Evidence of bleeding diathesis or coagulopathy

• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study

• Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment.

• History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment.

• Serious, non-healing wound, ulcer (including gastrointestinal), or bone fracture.

• Any condition which in the investigator's opinion makes the subject unsuitable for study participation.

• Pregnant (positive pregnancy test) or lactating. Refusal or inability to use highly effective means of contraception (men and women) in participants of child-bearing potential.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of California Los Angeles	Los Angeles	California	United States	90095
2	Massachusetts General Hosptial	Boston	Massachusetts	United States	02114
3	Dana-Farber Cancer Institute	Boston	Massachusetts	United States	02115
4	University of Massachusetts, Worcester	Worcester	Massachusetts	United States	01655
5	New York - Presbyterian/Columbia University Medical Center	New York	New York	United States	10032
6	University of Virginia	Charlottesville	Virginia	United States	22908

Sponsors and Collaborators

• Dana-Farber Cancer Institute
• Amgen

Investigators

• Principal Investigator: David Reardon, MD, Dana-Farber Cancer Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: David Reardon, MD, Principal Investigator, Dana-Farber Cancer Institute
• ClinicalTrials.gov Identifier: NCT01290263
• Other Study ID Numbers: 12-185
• First Posted: Feb 4, 2011
• Last Update Posted: Jul 2, 2017
• Last Verified: Jun 1, 2017

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by David Reardon, MD, Principal Investigator, Dana-Farber Cancer Institute: Glioblastoma; GBM; Brain Tumor; Glioma
• Additional relevant MeSH terms: Glioblastoma; Bevacizumab; Trebananib

Study Results

Participant Flow

Recruitment Details	As of August 1, 2013, Cohort A was closed to new accrual following early interim analysis of first 10 participants enrolled on study showed insufficient efficacy per design.

Arm/Group Title	Cohort A: AMG 386 30 mg/kg	Cohort B Phase I Dose Level 0: AMG 386 15 mg/kg + Bevacizumab	Cohort B Phase I Dose Level +1: AMG 386 30 mg/kg + Bevacizumab	Cohort B Phase II: AMG 386 30 mg/kg + Bevacizumab	All Cohort B Participants: AMG 386 + Bevacizumab
Arm/Group Description	Cohort A participants received AMG 386 intravenously (IV) at 30 mg/kg on days 1, 8, 15 and 22 of each 28 day cycle. Participants were treated until disease progression or unacceptable toxicity.	Cohort B Phase I Dose Level 0 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the original starting dose AMG 386 of 15 mg/kg intravenously (IV) on days 1, 8, 15 and 22. Participants were treated until disease progression or unacceptable toxicity.	Cohort B Phase I Dose Level +1 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and AMG 386 of 15 mg/kg intravenously (IV) on days 1, 8, 15 and 22. Participants were treated until disease progression or unacceptable toxicity. As of June 2014, the maximum tolerated dose (MTD) of bevacizumab + AMG 386 was determined to be dose level +1, AMG 386 30 mg + kg.	Participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the maximum tolerated AMG 386 dose established in the Phase I Cohort B study, AMG 386 of 30 mg/kg intravenously (IV) on days 1, 8, 15 and 22. Participants were treated until disease progression or unacceptable toxicity.	Phase I & II Cohort B participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the assigned AMG 386 dose of 15 mg/kg or 30 mg/kg intravenously (IV) on days 1, 8, 15 and 22. Participants were treated until disease progression or unacceptable toxicity.
Period Title: Overall Study
STARTED	11	3	7	27	37
COMPLETED	0	0	0	0	0
NOT COMPLETED	11	3	7	27	37

Baseline Characteristics

Arm/Group Title	Cohort B: AMG 386 + Bevacizumab	Cohort A: AMG 386 30 mg/kg	Total
Arm/Group Description	All Phase I & II Cohort B participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the assigned AMG 386 dose of 15 mg/kg or 30 mg/kg intravenously (IV) on days 1, 8, 15 and 22. Participants were treated until disease progression or unacceptable toxicity.	All cohort A participants received AMG 386 intravenously (IV) at 30 mg/kg on days 1, 8, 15 and 22 of each 28 day cycle. Participants were treated until disease progression or unacceptable toxicity.	Total of all reporting groups
Overall Participants	37	11	48
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	63	62	62
Sex: Female, Male (Count of Participants)
Female	11 29.7%	5 45.5%	16 33.3%
Male	26 70.3%	6 54.5%	32 66.7%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%	1 9.1%	1 2.1%
Not Hispanic or Latino	35 94.6%	10 90.9%	45 93.8%
Unknown or Not Reported	2 5.4%	0 0%	2 4.2%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%
Asian	0 0%	0 0%	0 0%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%
Black or African American	0 0%	0 0%	0 0%
White	35 94.6%	10 90.9%	45 93.8%
More than one race	1 2.7%	1 9.1%	2 4.2%
Unknown or Not Reported	1 2.7%	0 0%	1 2.1%
Number of Prior Relapses (participants) [Number]
1	23 62.2%	8 72.7%	31 64.6%
2	14 37.8%	2 18.2%	16 33.3%
3	0 0%	1 9.1%	1 2.1%

Outcome Measures

1. Primary Outcome

Title	6-Month Progression-Free Survival (PFS6) [Cohort A and Cohort B]
Description	PFS6 is the proportion of patients remaining alive and progression-free at 6-months from study entry. Progressive disease was established based on Response Assessment in Neuro-Oncology (RANO) criteria (Wen et al JCO 2010). RANO criteria has 5 potential categories: Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive disease (PD) and Unknown status. CR: disappearance of all enhancing lesions, stable or improved non-enhancing lesions, and stable or improved clinically. PR: >= 50% decrease in sum of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, stable or improved non- enhancing lesions, and stable or improved clinically. PD: > 25% increase in sum of perpendicular diameters of all measurable enhancing lesions, significant increase of non-enhancing lesions, any new lesions, clear clinical deterioration, failure to return for evaluation due to death or deteriorating condition. SD: d
Time Frame	6 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	All Cohort B Participants: AMG 386 + Bevacizumab	Cohort A: AMG 386 30 mg/kg
Arm/Group Description	All Phase I & II Cohort B participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the assigned AMG 386 dose of 15 mg/kg or 30 mg/kg intravenously (IV) on days 1, 8, 15 and 22. Participants were treated until disease progression or unacceptable toxicity.	All cohort A participants received AMG 386 intravenously (IV) at 30 mg/kg on days 1, 8, 15 and 22 of each 28 day cycle. Participants were treated until disease progression or unacceptable toxicity.
Measure Participants	37	11
Number (95% Confidence Interval) [proportion of participants]	0.243 0.7%	0 0%

2. Primary Outcome

Title	AMG 386 Maximum Tolerated Dose (MTD) [Cohort B Phase I]
Description	The MTD of weekly AMG 386 intravenously (IV) in combination with bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle is determined by the number of participants who experience a dose limiting toxicity (DLT). See subsequent primary outcome measure for the DLT definition. The MTD is defined as the highest dose at which fewer than one-third of patients experience a DLT. If no DLTs are observed, the MTD is not reached but the highest dose received may be the Recommended Phase II Dose (RP2D).
Time Frame	Participants were assessed weekly while on study; the observation period for MTD evaluation was the first 28 days of study treatment.

Outcome Measure Data

Analysis Population Description

All phase I Cohort B participants who received at least one dose of the study drug were evaluable for MTD. A participant was replaceable if they are taken off of study treatment due to progressive disease or withdrawal from study during before they completed the 28 day DLT period.

Arm/Group Title	Cohort B Phase I Dose Level 0: AMG 386 15 mg/kg + Bevacizumab	Cohort B Phase I Dose Level +1: AMG 386 30 mg/kg + Bevacizumab
Arm/Group Description	Cohort B Phase I Dose Level 0 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the original starting dose AMG 386 of 15 mg/kg intravenously (IV) on days 1, 8, 15 and 22. Participants were treated until disease progression or unacceptable toxicity.	Cohort B Phase I Dose Level +1 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and AMG 386 of 15 mg/kg intravenously (IV) on days 1, 8, 15 and 22. Participants were treated until disease progression or unacceptable toxicity. As of June 2014, the maximum tolerated dose (MTD) of bevacizumab + AMG 386 was determined to be dose level +1, AMG 386 30 mg/kg.
Measure Participants	3	7
Number [mg/kg intravenously on days 1 and 15]	30	30

3. Secondary Outcome

Title	Best Radiographic Response [Cohort A and Cohort B]
Description	Radiographic response was established based on Response Assessment in Neuro-Oncology (RANO) criteria (Wen et al JCO 2010) with 5 potential categories: Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive disease (PD) and Unknown status. CR: disappearance of all enhancing lesions, stable or improved non-enhancing lesions, and stable or improved clinically. PR: >= 50% decrease in sum of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, stable or improved non- enhancing lesions, and stable or improved clinically. PD: > 25% increase in sum of perpendicular diameters of all measurable enhancing lesions, significant increase of non-enhancing lesions, any new lesions, clear clinical deterioration, failure to return for evaluation due to death or deteriorating condition. SD: does not qualify for CR, PR or PD, stable non-enhancing lesions, and stable clinically.
Time Frame	Disease was assessed radiographically for response every 8 weeks.

Outcome Measure Data

Analysis Population Description

All participants who received at least one dose of the study drug were evaluable for response.

Arm/Group Title	All Cohort B Participants: AMG 386 + Bevacizumab	Cohort A: AMG 386 30 mg/kg
Arm/Group Description	All Phase I & II Cohort B participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the assigned AMG 386 dose of 15 mg/kg or 30 mg/kg intravenously (IV) on days 1, 8, 15 and 22. Participants were treated until disease progression or unacceptable toxicity.	All cohort A participants received AMG 386 intravenously (IV) at 30 mg/kg on days 1, 8, 15 and 22 of each 28 day cycle. Participants were treated until disease progression or unacceptable toxicity.
Measure Participants	37	11
Complete Response	0 0%	0 0%
Partial Response	4 10.8%	0 0%
Stable Disease	20 54.1%	1 9.1%
Progressive Disease	10 27%	8 72.7%
Unknown	3 8.1%	2 18.2%

4. Secondary Outcome

Title	Overall Survival (OS) [Cohort A and Cohort B]
Description	OS based on Kaplan-Meier is defined as the time from study entry to death or date last known alive.
Time Frame	Participants were followed long-term for survival every 3 to 4 months from the end of treatment until death or lost to follow-up. On Cohort A and B participants were followed up to 554 days and 442 days.

Outcome Measure Data

Analysis Population Description

All participants who received at least one dose of the study drug were followed for OS.

Arm/Group Title	All Cohort B Participants: AMG 386 + Bevacizumab	Cohort A: AMG 386 30 mg/kg
Arm/Group Description	All Phase I & II Cohort B participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the assigned AMG 386 dose of 15 mg/kg or 30 mg/kg intravenously (IV) on days 1, 8, 15 and 22. Participants were treated until disease progression or unacceptable toxicity.	All cohort A participants received AMG 386 intravenously (IV) at 30 mg/kg on days 1, 8, 15 and 22 of each 28 day cycle. Participants were treated until disease progression or unacceptable toxicity.
Measure Participants	37	11
Median (Full Range) [days]	285	341

5. Secondary Outcome

Title	Progression-Free Survival (PFS) [Cohort A and Cohort B]
Description	PFS based on Kaplan-Meier is defined as the time from study entry to the earliest documentation of disease progression or death. Progressive disease was established based on Response Assessment in Neuro-Oncology (RANO) criteria (Wen et al JCO 2010).
Time Frame	Disease was assessed radiographically to document clinical progression every cycle on treatment and post-treatment every 8 weeks. On Cohort A and B participants were followed for progression up to 36 days and 166 days.

Outcome Measure Data

Analysis Population Description

All participants who received at least one dose of the study drug were evaluable for PFS.

Arm/Group Title	All Cohort B Participants: AMG 386 + Bevacizumab	Cohort A: AMG 386 30 mg/kg
Arm/Group Description	All Phase I & II Cohort B participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the assigned AMG 386 dose of 15 mg/kg or 30 mg/kg intravenously (IV) on days 1, 8, 15 and 22. Participants were treated until disease progression or unacceptable toxicity.	All cohort A participants received AMG 386 intravenously (IV) at 30 mg/kg on days 1, 8, 15 and 22 of each 28 day cycle. Participants were treated until disease progression or unacceptable toxicity.
Measure Participants	37	11
Median (Full Range) [days]	108	21

6. Primary Outcome

Title	AMG 386 Dose Limiting Toxicity (DLT) [Cohort B Phase I]
Description	A DLT is defined as an adverse event that (a) is related to the AMG 386 and/or bevacizumab with an attribution of possible, probable, or definite, and (b) occurs during and/or begins during the first 28 days of the study treatment, and (c) meets any of the following criteria: >= grade 3 thrombocytopenia; grade 4 neutropenia lasting > 7 days; grade 4 anemia lasting > 7 days despite transfusion or growth factors; febrile neutropenia if ANC<0.5x10^9/L; clinically significant grade 3 non-hematologic toxicity despite maximal medical therapy lasting > 7 days, with the exception of grade 3 proteinuria which was considered a DLT if lasting > 14 days; grade 3 non-hematologic toxicity resulting in study drug discontinuation; grade 4 non-hematologic toxicity; >= grade 1 new CNS hemorrhage; >= grade 2 non-CNS hemorrhage.
Time Frame	Participants were assessed weekly while on study; the observation period for DLT evaluation was the first 28 days of study treatment.

Outcome Measure Data

Analysis Population Description

All phase I Cohort B participants who completed 28 days on study treatment were evaluable. A participant was replaceable if they are taken off of study treatment due to progressive disease or withdrawal from study during before they completed the 28 day DLT period.

Arm/Group Title	Cohort B Phase I Dose Level 0: AMG 386 15 mg/kg + Bevacizumab	Cohort B Phase I Dose Level +1: AMG 386 30 mg/kg + Bevacizumab
Arm/Group Description	Cohort B Phase I Dose Level 0 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the original starting dose AMG 386 of 15 mg/kg intravenously (IV) on days 1, 8, 15 and 22. Participants were treated until disease progression or unacceptable toxicity.	Cohort B Phase I Dose Level +1 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and AMG 386 of 15 mg/kg intravenously (IV) on days 1, 8, 15 and 22. Participants were treated until disease progression or unacceptable toxicity. As of June 2014, the maximum tolerated dose (MTD) of bevacizumab + AMG 386 was determined to be dose level +1, AMG 386 30 mg/kg.
Measure Participants	3	7
Number [participants]	0 0%	0 0%

Adverse Events

Time Frame	Assessed each treatment cycle (1 cycle = 28 days) from time of first dose and up to day 30 post-treatment. Treatment duration in cycles was a median (range) of 1 (1-2) Cohort A and 4 (1-20) Cohort B.
Adverse Event Reporting Description	Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with AMG386 and/or bevacizumab treatment-attribution of at least possibly and causing a hospitalization, deemed serious by the treating investigator or grade 5 events per CTCAE v4. Other AEs were defined as events with AMG386 and/or bevacizumab treatment-attribution of at least possibly and not requiring a hospitalization or deemed non-serious by treating investigator.
Arm/Group Title	Cohort B: AMG 386 + Bevacizumab		Cohort A: AMG 386 30 mg/kg
Arm/Group Description	All Phase I & II Cohort B participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the assigned AMG 386 dose of 15 mg/kg or 30 mg/kg intravenously (IV) on days 1, 8, 15 and 22. Participants were treated until disease progression or unacceptable toxicity.		All cohort A participants received AMG 386 intravenously (IV) at 30 mg/kg on days 1, 8, 15 and 22 of each 28 day cycle. Participants were treated until disease progression or unacceptable toxicity.
All Cause Mortality
	Cohort B: AMG 386 + Bevacizumab		Cohort A: AMG 386 30 mg/kg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)
Serious Adverse Events
	Cohort B: AMG 386 + Bevacizumab		Cohort A: AMG 386 30 mg/kg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	5/37 (13.5%)		0/11 (0%)
Blood and lymphatic system disorders
Platelet count decreased	1/37 (2.7%)	1	0/11 (0%)	0
General disorders
Edema Limbs	1/37 (2.7%)	1	0/11 (0%)	0
Fatigue	1/37 (2.7%)	1	0/11 (0%)	0
Fatigue	1/37 (2.7%)	1	0/11 (0%)	0
Investigations
Neutrophil Count Decreased	1/37 (2.7%)	1	0/11 (0%)	0
Other (Not Including Serious) Adverse Events
	Cohort B: AMG 386 + Bevacizumab		Cohort A: AMG 386 30 mg/kg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	30/37 (81.1%)		8/11 (72.7%)
Blood and lymphatic system disorders
Anemia	2/37 (5.4%)	2	0/11 (0%)	0
Cardiac disorders
Atrial Flutter	1/37 (2.7%)	1	0/11 (0%)	0
Pericardial Effusion	1/37 (2.7%)	1	0/11 (0%)	0
Eye disorders
Blurred Vision	0/37 (0%)	0	1/11 (9.1%)	1
Blurred Vision	1/37 (2.7%)	1	0/11 (0%)	0
Other - Conjunctival Hemorrhage	1/37 (2.7%)	1	0/11 (0%)	0
Gastrointestinal disorders
Abdominal Pain	1/37 (2.7%)	1	1/11 (9.1%)	1
Abdominal Pain	0/37 (0%)	0	1/11 (9.1%)	1
Constipation	0/37 (0%)	0	2/11 (18.2%)	2
Constipation	1/37 (2.7%)	1	0/11 (0%)	0
Diarrhea	0/37 (0%)	0	1/11 (9.1%)	1
Diarrhea	1/37 (2.7%)	1	0/11 (0%)	0
Dry Mouth	0/37 (0%)	0	1/11 (9.1%)	1
Hemorrhoids	1/37 (2.7%)	1	0/11 (0%)	0
Nausea	3/37 (8.1%)	3	2/11 (18.2%)	2
Stomach Pain	1/37 (2.7%)	1	0/11 (0%)	0
Other - Indigestion/heartburn	0/37 (0%)	0	1/11 (9.1%)	1
General disorders
Edema Face	1/37 (2.7%)	1	0/11 (0%)	0
Edema Limbs	3/37 (8.1%)	3	1/11 (9.1%)	1
Edema Limbs	2/37 (5.4%)	2	0/11 (0%)	0
Fatigue	3/37 (8.1%)	3	0/11 (0%)	0
Fatigue	3/37 (8.1%)	3	2/11 (18.2%)	2
Infusion Related Reaction	1/37 (2.7%)	1	0/11 (0%)	0
Infusion Site Reaction	1/37 (2.7%)	1	0/11 (0%)	0
Localized Edema	1/37 (2.7%)	1	0/11 (0%)	0
Gait Disturbance	0/37 (0%)	0	1/11 (9.1%)	1
Injury, poisoning and procedural complications
Bruising	1/37 (2.7%)	1	0/11 (0%)	0
Vascular Access Complication	1/37 (2.7%)	1	0/11 (0%)	0
Investigations
Alanine Aminotransferase Increased	2/37 (5.4%)	2	0/11 (0%)	0
Alkaline Phosphatase Increased	1/37 (2.7%)	1	0/11 (0%)	0
Aspartate Aminotransferase Increased	2/37 (5.4%)	2	0/11 (0%)	0
Blood Bilirubin Increased	1/37 (2.7%)	1	0/11 (0%)	0
Cardiac Troponin I Increased	1/37 (2.7%)	1	0/11 (0%)	0
Neutrophil Count Decreased	1/37 (2.7%)	1	0/11 (0%)	0
Neutrophil Count Decreased	1/37 (2.7%)	1	0/11 (0%)	0
Platelet Count Decreased	4/37 (10.8%)	4	0/11 (0%)	0
Platelet Count Decreased	1/37 (2.7%)	1	0/11 (0%)	0
White Blood Cell Decreased	1/37 (2.7%)	1	0/11 (0%)	0
Metabolism and nutrition disorders
Anorexia	1/37 (2.7%)	1	0/11 (0%)	0
Hyperglycemia	2/37 (5.4%)	2	0/11 (0%)	0
Hypokalemia	2/37 (5.4%)	2	0/11 (0%)	0
Hyponatremia	2/37 (5.4%)	2	1/11 (9.1%)	1
Hypophosphatemia	1/37 (2.7%)	1	0/11 (0%)	0
Musculoskeletal and connective tissue disorders
Arthralgia	2/37 (5.4%)	2	0/11 (0%)	0
Generalized Muscle Weakness	1/37 (2.7%)	1	1/11 (9.1%)	1
Muscle Weakness Lower Limb	0/37 (0%)	0	1/11 (9.1%)	1
Myalgia	1/37 (2.7%)	1	0/11 (0%)	0
Nervous system disorders
Dizziness	1/37 (2.7%)	1	0/11 (0%)	0
Headache	2/37 (5.4%)	2	1/11 (9.1%)	1
Intracranial Hemorrhage	1/37 (2.7%)	1	0/11 (0%)	0
Presyncope	1/37 (2.7%)	1	0/11 (0%)	0
Psychiatric disorders
Confusion	1/37 (2.7%)	1	0/11 (0%)	0
Insomnia	1/37 (2.7%)	1	0/11 (0%)	0
Insomnia	0/37 (0%)	0	1/11 (9.1%)	1
Renal and urinary disorders
Hematuria	3/37 (8.1%)	3	0/11 (0%)	0
Proteinuria	1/37 (2.7%)	1	0/11 (0%)	0
Proteinuria	1/37 (2.7%)	1	0/11 (0%)	0
Respiratory, thoracic and mediastinal disorders
Epistaxis	3/37 (8.1%)	3	0/11 (0%)	0
Hoarseness	6/37 (16.2%)	6	1/11 (9.1%)	1
Skin and subcutaneous tissue disorders
Alopecia	2/37 (5.4%)	2	0/11 (0%)	0
Rash Maculo-papular	1/37 (2.7%)	1	0/11 (0%)	0
Skin Ulceration	1/37 (2.7%)	1	0/11 (0%)	0
Other - Livedo Reticularis	1/37 (2.7%)	1	0/11 (0%)	0
Vascular disorders
Hypertension	2/37 (5.4%)	2	0/11 (0%)	0
Hypertension	10/37 (27%)	10	0/11 (0%)	0
Hypertension	3/37 (8.1%)	3	0/11 (0%)	0
Thromboembolic Event	2/37 (5.4%)	2	0/11 (0%)	0
Thromboembolic Event	1/37 (2.7%)	1	0/11 (0%)	0

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.